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Abstract
Background: Neurexin is a synaptic cell adhesion protein critical for synapse formation and function. Mutations in neurexin
and neurexin-interacting proteins have been implicated in several neurological diseases. Previous studies have described
Drosophila neurexin mutant phenotypes in third instar larvae and adults. However, the expression and function of
Drosophila neurexin early in synapse development, when neurexin function is thought to be most important, has not been
described.
Methodology/Principal Findings: We use a variety of techniques, including immunohistochemistry, electron microscopy, in
situ hybridization, and electrophysiology, to characterize neurexin expression and phenotypes in embryonic Drosophila
neuromuscular junctions (NMJs). Our results surprisingly suggest that neurexin in embryos is present both pre and
postsynaptically. Presynaptic neurexin promotes presynaptic active zone formation and neurotransmitter release, but along
with postsynaptic neurexin, also suppresses formation of ectopic glutamate receptor clusters. Interestingly, we find that loss
of neurexin only affects receptors containing the subunit GluRIIA.
Conclusions/Significance: Our study extends previous results and provides important detail regarding the role of neurexin
in Drosophila glutamate receptor abundance. The possibility that neurexin is present postsynaptically raises new
hypotheses regarding neurexin function in synapses, and our results provide new insights into the role of neurexin in
synapse development.
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Introduction
The synaptic clefts of both mammalian central glutamatergic
synapses and Drosophila NMJs are approximately 20 nanometers
wide and contain extracellular domains of cell adhesion proteins
and associated molecules [1,2,3,4]. A number of synapse-specific
cell adhesion molecules, including neurexin, have been identified,
and several have been proposed to be important for triggering
synapse formation and serving as anchors for aggregation of other
synaptic molecules [5,6,7].
Neurexin first attracted attention as a receptor for alpha
latrotoxin, a black widow spider venom component that causes
massive neurotransmitter release [8,9]. Recent genetic studies
have linked mutations in human neurexin to autism, mental
retardation, and schizophrenia [10,11,12,13,14,15,16,17,18,19].
Thus, neurexin clearly plays an important role in nervous system
development and function.
The precise role of neurexin has been difficult to study due to
the protein’s complexity. Mammalian genomes contain three
neurexin genes. Each gene drives expression of two primary
neurexin isoforms via alternative promoters: a full-length (alpha)
neurexin, and a short (beta) neurexin that contains a common C-
terminus [8,20,21]. Each of these six primary mammalian
neurexin transcripts can then be alternatively spliced to form
potentially thousands of different proteins [22,23].
Despite this complexity, important progress has been made.
Neurexin has been shown to bind to several key synaptic proteins,
including the synaptic vesicle protein synaptotagmin, the synaptic
scaffolding proteins Mint and CASK, and the cell adhesion
molecules neuroligin and LRRTM2 [24,25,26,27,28]. Neurexin is
thought to nucleate aggregation and organization of synaptic
components around a transynaptic cell adhesion complex.
Consistent with this, neurexin-neuroligin and neurexin-LRRTM2
interactions promote synapse formation and/or aggregation of
synaptic molecules [28,29,30,31,32,33,34,35].
The first complete knockout of neurexin was achieved in
Drosophila, which appears to possess only a single relatively simple
neurexin similar to mammalian alpha neurexin [36,37]. Surpris-
ingly, Drosophila neurexin null mutants are viable and fertile (albeit
with reduced lifespan), but show reduced synapse number and
impaired synaptic transmission [36,37]. Behavioral tests also
reveal impairments in larval learning [36].
Here, we extend previous studies by introducing novel Drosophila
neurexin mutant alleles and examining neurexin mutant synapses
in embryonic Drosophila during the NMJ formation and the initial
wave of synaptogenesis. Synapse loss is an important part of
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synapse number previously observed in neurexin mutants could
represent impairment in initial synapse formation or destabiliza-
tion and subsequent loss of synapses. Our study addresses this
question directly. We also consider whether Drosophila neurexin
might function postsynaptically as well as presynaptically, and
provide more detail regarding the role that neurexin plays with
regard to postsynaptic glutamate receptor abundance in Drosophila
neuromuscular junctions (NMJs).
Results
We isolated several independent Drosophila neurexin mutant
alleles by mobilization of P{Mi}Nrx-1{MB00002}, a minos P-
element in the Drosophila neurexin gene. One of these alleles was
nrx[313], which we selected for further study because it appeared
to be a null allele (see below). Previous studies [37,39] have shown
that Drosophila neurexin is highly abundant in mature larval
neuromuscular junctions (110–120 h after egg laying, AEL). Using
independently generated anti-neurexin antibodies (see methods),
we confirmed the presence of neurexin in larval NMJs, and
extended this analysis to embryonic NMJs (22–24 h AEL; Fig. 1).
As expected, we found that neurexin immunoreactivity was also
abundant in embryonic NMJs (Fig. 1). Neurexin NMJ immuno-
reactivity was eliminated in embryos homozygous for
Df(3R)Exel6191, a deficiency that completely removes the neurexin
gene (Fig. 1). Neurexin NMJ immunoreactivity was also eliminated
in homozygous nrx[313] mutants, in nrx[313]/Df(3R)Exel6191
mutants, and in nrx[313]/nrx[241] mutants (Fig. 1), where nrx[241]
is a previously-described small deficiency that deletes the neurexin
coding region [37]. Neurexin immunoreactivity in NMJs could be
restored in nrx[313]/nrx[241] mutants by transgenic expression of
a neurexin cDNA (DJ690Gal4/UAS-nrx;nrx[313]/nrx[241]). Taken
together, these data suggest that our antibody is specific for
neurexin in embryonic NMJs, that neurexin is abundant in
embryonic NMJs, and that nrx[313] is a protein null allele or very
strong hypomorph.
Transgenic expression of neurexin RNAi also reduced neurexin
immunoreactivity in embryonic NMJs (Fig. 1). Strong ubiquitous
expression of neurexin RNAi (TubGal4/nrx.RNAi) reduced neur-
exin immunoreactivity in embryonic NMJs to undetectable
levels, comparable to nrx[313] or the neurexin gene deletions
Df(3R)Exel6191 and nrx[241] (Fig. 1). However, we could only
eliminate half the neurexin NMJ immunoreactivity by strong
neuronal (presynaptic) expression of neurexin RNAi (ElavGal4/
nrx1.RNAi; Fig. 1). Surprisingly, we were also able to eliminate
half the neurexin NMJ immunoreactivity by muscle-specific
(postsynaptic) expression of neurexin RNAi (24BGal4/nrx1.RNAi;
Fig. 1). The simplest conclusion, based on these data, is that
neurexin in Drosophila embryonic NMJs is expressed both pre
and postsynaptically.
To further explore the idea that neurexin might be expressed in
postsynaptic muscle cells, we analyzed neurexin immunoreactivity
in embryonic NMJs using immuno electron microscopy following
high-pressure freeze fixation and freeze substitution (HPF/FS)
(Fig. 2). In one set of experiments, we counted 293 beads in 24
NMJ sections from 2 different embryos. Most immunoreactivity
was found in presynaptic terminals (Fig. 2A, D). However, a
considerable amount of immunoreactivity was also found in
postsynaptic muscle (Fig. 2B–D). We measured nonspecific
background immunoreactivity in the same sections by counting
beads in all other ‘negative control’ tissues (gut, cuticle, fat bodies,
or bacteria surrounding animals during HPF). As expected, very
little immunoreactivity was observed in negative control tissue. To
ensure that the beads we observed in muscle did not represent
spurious background, we analyzed another 100 sections from 12
different NMJs in 3 more animals under higher stringency/lower
antibody conditions. Under these conditions, no beads were
observed in negative control tissues, but the number of beads in
muscle compared to nerve terminal was proportionally the same as
measured under the low stringency conditions. Specifically, 14 of
21 beads (67%) were in presynaptic terminals, and 7 of 21 beads
(33%) were in postsynaptic muscle. These data, like the
immunohistochemical data after RNAi, suggest that neurexin
protein near embryonic NMJs is present in both presynaptic nerve
terminals and postsynaptic muscle.
If Drosophila neurexin is expressed in postsynaptic body wall
muscles, then we should be able to detect neurexin expression in
muscles using RNA in situ hybridization. We therefore performed
RNA in situ experiments on whole embryos (Fig. 3). Consistent
with previous reports [36,37], we saw strong neurexin expression
in the nervous system (Fig. 3). However, in late-stage embryos after
body wall muscle formation we also saw weak body wall muscle
expression of neurexin (Fig. 3C). Because cuticle formation in late-
stage embryos can limit detection of muscle gene expression, we
also examined neurexin RNA expression in filleted late-stage
embryos (Fig. 3E–F). Neurexin expression was prominent in the
nervous system of filleted embryos, consistent with strong nervous
system expression of neurexin and the fact that the nervous system
is many cell layers thick. However, neurexin expression was also
detectable in body wall muscles (Fig. 3E), including individual
ventral longitudinal muscles 6 and 7 – the same muscles that form
the postsynaptic side of the NMJs examined immunohistochem-
ically (Fig. 1).
We next examined the form and function of embryonic NMJs
after loss of neurexin. Previous reports [36,37] showed that
neurexin is not essential for NMJ formation in larvae and adults,
but cannot rule out the possibility of defects or delays early in
development, for which the animal might compensate later. We
analyzed NMJ synapse ultrastructure after HPF/FS of embry-
o n i cN M J s( F i g .4 ) .E v e ni nt h ec o m p l e t ea b s e n c eo fn e u r e x i n
(Df(3R)Exel6191), NMJ synapses appeared relatively normal,
except as also noted in larval neurexin mutant NMJs [37], pre
and postsynaptic densities were incompletely apposed in the
absence of neurexin. The number of synaptic vesicles, dense
core vesicles, active zone diameter, and postsynaptic density
(PSD) diameter in nrx mutants were all statistically indistin-
guishable from wildtype NMJ synapses. However, the overall
synapse density per NMJ appeared lower without neurexin. For
example, serial sectioning of NMJs from WT animals revealed
synapses in 12 in 38 sections (32%). In contrast, only 9 of 104
NMJ sections (9%) from Df(3R)Exel6191 mutant embryos had
synapses.
To explore the apparent loss of synapses per NMJ further, we
stained embryonic NMJs using anti-HRP antibodies (which allow
visualization of the entire presynaptic NMJ arborization), and anti-
bruchpilot (BRP) antibodies, which label individual active zones.
As shown in Figs. 5A–C, NMJ size and number of active zones per
NMJ were both significantly reduced in the absence of neurexin
(nrx[313]/Df(3R)Exel6191). RNAi knockdown of neurexin in
presynaptic neurons (ElavGal4/nrx.RNAi) also reduced NMJ size
and active zones per NMJ (Fig. 5A–C). Postsynaptic knockdown of
neurexin (24BGal4/nrx.RNAi) had no detectable effect on NMJ size
or number of active zones per NMJ (Fig. 5A–C). Neither active
zone density within the NMJ or active zone size were affected by
loss of neurexin (Fig. 5A, D–E). We conclude, based on our EM
and immunohistochemical data, that loss of neuronal neurexin
reduces active zone formation during embryogenesis.
Drosophila Neurexin
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patch-clamped muscle 6 NMJs in embryos — the same junctions
that we analyzed immunohistochemically (Fig. 5). As shown in
Fig. 6, electrical stimulation of presynaptic motor nerve axons in
wildtype embryos trigger large (,1500 pA) excitatory junction
currents (EJCs). EJC amplitudes were significantly reduced in
neurexin mutants (nrx[313]/Df and Df/Df; Fig. 6). Presynaptic
expression of neurexin RNAi (ElavGal4/nrx.RNAi) also reduced EJC
Figure 1. Neurexin expression in embryonic NMJs after specific genetic manipulations. A: representative confocal micrographs of
embryonic muscle 6/7 NMJs stained with antibodies against the N-terminus of neurexin (magenta) and HRP (green). B: Neurexin immunoreactivity on
western blots is absent in preimmune negative controls and in Df(3R)Exel6191, a genomic deletion that completely removes the neurexin locus. C:
quantification of neurexin immunoreactivity from images like those shown in A. Wild type and UAS-nrx1.RNAi are controls. 24BGal4/nrx1.RNAi and
ElavGal4/nrx.RNAi represent expression of neurexin RNAi in muscles and neurons, respectively. TubGal4/nrx1.RNAi represents expression of neurexin
RNAi in all tissues. Df represents Df(3R)Exel6191. nrx[313] and nrx[241] are neurexin mutant alleles. DJ690Gal4/UAS-nrx;nrx[313]/nrx[241] represents
both muscle and neuron expression of neurexin cDNA in a nrx[313]/nrx[241] mutant background. Numbers in parentheses represent N, the number of
animals examined.
doi:10.1371/journal.pone.0011115.g001
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(24BGal4/nrx.RNAi) had no effect on EJC amplitude (Fig. 6).
The frequency of spontaneous excitatory junction currents was not
significantly altered in any genotype (Fig. 6). To check whether
reduced EJC amplitudes might be due to reduced calcium
sensitivity for neurotransmitter release, we compared EJC
amplitudes recorded from wild type and neurexin mutants
(nrx[313]/Df) in two different calcium concentrations (Fig. 7).
Both genotypes showed similar calcium sensitivity (Fig. 7). These
results suggest that reduced EJC amplitudes are a consequence of
fewer synapses in neurexin mutants.
We also explored whether neurexin might regulate expression,
clustering, or function of postsynaptic glutamate receptors.
Drosophila embryonic/larval NMJs contain two molecularly,
biophysically, and pharmacologically distinct subtypes of postsyn-
aptic glutamate receptor: ‘A-type’ and ‘B-type’. The in vivo
molecular composition of both receptor subtypes has been
determined [40,41,42,43,44,45]. A-type receptors contain the
subunits GluRIIA, GluRIIC, GluRIID, and GluRIIE. B-type
receptors contain the subunits GluRIIB, GluRIIC, GluRIID, and
GluRIIE. Although there is some mixing of glutamate receptor
subtypes during larval development [43], A- and B-type receptors
in embryonic NMJs are spatially segregated into homotypic
clusters that are differentially associated with the postsynaptic
cytoskeleton [46,47].
We measured significantly increased GluRIIC immunoreactiv-
ity in embryonic NMJs of neurexin mutants (nrx[313]Df and Df/
Df), and after presynaptic or postsynaptic RNAi knockdown of
neurexin (Fig. 8A). This change could be due to an increase in A-
type receptors, B-type receptors, or both A- and B-type receptors.
To determine which was the case, we used GluRIIA and GluRIIB-
specific antibodies. As shown in Fig. 8B, GluRIIA immunoreac-
tivity was increased in neurexin mutants (nrx[313]Df and Df/Df),
and after presynaptic or postsynaptic RNAi knockdown of
neurexin (Fig. 8B). This increase was not accompanied by a
change in the size of individual A-type receptor clusters (Fig. 8D),
and there was no change in GluRIIB immunoreactivity (Fig. 8C,
E). Because loss of neurexin caused the number of GluRIIA
Figure 2. Immuno electron micrographs from embryos showing neurexin protein immunoreactivity in both presynaptic terminals
(A), and in postsynaptic muscle (B,C). Synapses (marked by asterisks) are indicated by the presence of electron dense membrane and, in many
cases (panels A, B, B inset), by distinctively-shaped presynaptic electron dense structures (‘T-bars’). Arrows in each panel point to 10 nm beads
indicating positive neurexin immunoreactivity. D: Average density of 10 nm beads in neuronal axon terminals, body wall musculature, and other
tissue (cuticle, gut, or bacteria surrounding the animal during HPF), calculated from each section. The total number of beads counted, and the total
area of each tissue examined across all sections, is also indicated.
doi:10.1371/journal.pone.0011115.g002
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clusters, the A- to B-type receptor ratio in PSDs was shifted in
favor of A-type – an effect visible when co-staining with GluRIIA
and GluRIIB antibodies (Fig. 8F). We also observed ‘ectopic’
GluRIIA immunoreactivity that did not colocalize with that of the
active zone protein bruchpilot (BRP) [48] (Fig. 8G). Postsynaptic
GluRIIA immunoreactivity normally colocalizes with presynaptic
BRP [49].
Figure 4. Embryonic synapse ultrastructure in the absence of neurexin. Homozygous Df(3R)Exel6191 mutants (abbreviated ‘Df/Df’) are
devoid of neurexin. Synaptic vesicles, electron dense presynaptic membrane and presynaptic dense projections at active zones (AZ) are visible in
both wildtype and homozygous Df(3R)Exel6191 mutant embryonic body wall NMJs. Similarly, both WT and Df(3R)Exel6191 mutant NMJ synapses show
postsynaptic electron dense membrane (PSD). NMJ synapses in Df(3R)Exel6191 mutants show no significant changes in the number of synaptic
vesicles, diameter of AZs, or diameter of PSDs, compared to wildtype NMJ synapses. However, the electron dense postsynaptic muscle membrane in
Df(3R)Exel6191 mutants sometimes extends beyond the presynaptic specialization, or is not associated with any visible presynaptic specialization. In
some cases, we serial sectioned individual synapses to confirm that apparently misaligned PSDs did not pair with an AZ in a neighboring section. 142
sections from several animals were analyzed for the active zone & PSD statistics. For quantification, measurements were made from all available
sections of a synapse and then averaged together to produce a single measurement for each synapse. N (indicated in figure) represents the number
of unique NMJs that were sectioned.
doi:10.1371/journal.pone.0011115.g004
Figure 3. Neurexin mRNA expression in Drosophila embryos, detected using RNA in situ hybridization. A: Neurexin mRNA expression in
Drosophila embryos. RNA in situ hybridization reveals no detectable neurexin mRNA expression early in embryogenesis (5-7 h after fertilization/AF). B:
As neuronal differentiation proceeds at 10-11 h AF, however, neurexin mRNA expression is detectable throughout the central nervous system (CNS).
C: Late in embryogenesis (16-22 h AF), during early neuromuscular junction formation, neurexin mRNA is abundant within both the CNS and faintly
visible in body wall muscles (BWM). E-G: Shown are filleted whole embryos (F, H) and higher magnification images of the body wall musculature
(E, G, I). Staining (dark blue color, representing neurexin expression) was abundant in the central nervous system (CNS) and body wall muscles. The
positions of ventral longitudinal muscles (VLMs) and muscles 6 and 7 (M6, M7) are indicated by white arrows. All NMJ experiments described in this
paper were performed on muscle 6/7 NMJs. Note the lack of staining in CNS and BWM in the sense negative controls (H,I).
doi:10.1371/journal.pone.0011115.g003
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GluRIIA abundance and localization. To test whether neurexin is
sufficient for proper GluRIIA abundance, we cloned a neurexin
cDNA and used it to express GFP-tagged neurexin. When this
neurexin transgene was overexpressed (both pre and postsynap-
tically) in a neurexin null mutant background (DJ690Gal4/UAS-
nrx;nrx[313]/nrx[241]), GluRIIA immunoreactivity in NMJs was
significantly reduced, compared to controls (Fig. 9).
To test explicitly whether postsynaptic neurexin plays a role in
GluRIIA abundance, and to confirm and detail a previous
suggestion that neurexin also suppresses GluRIIA in larvae [37],
we overexpressed neurexin exclusively in postsynaptic muscle in a
wildtype background and quantified GluRIIA immunoreactivity
in larval NMJs (Figs. 10,11). GFP-tagged neurexin expressed
exclusively in postsynaptic muscle localized to the NMJ, and GFP
fluorescence overlapped with anti-neurexin antibody staining
(Fig. 10). GluRIIA immunoreactivity in the larval NMJ was
reduced after postsynaptic overexpression of neurexin (Fig. 11). In
contrast, GluRIIB immunoreactivity remained unchanged
(Fig. 11).
To test whether the increased GluRIIA and GluRIIC immunore-
activity observed in neurexin mutants might correlate with increased
receptor function, we pressure ejected glutamate onto NMJs and
recorded glutamate-gated currents after loss and knockdown of
neurexin in embryos (Fig. 12). There was no change in the amplitude
of glutamate-gated currents after loss of neurexin (Fig. 12A, C).
However, glutamate-gated currents in neurexin mutants tended to be
highly variable and often prolonged (Decay time constant 95%
Figure 5. Loss of presynaptic neurexin leads to smaller NMJs with fewer active zones in embryo. A: representative confocal images of
embryonic muscle 6/7 NMJs stained with antibodies against bruchpilot (BRP; magenta) to mark active zones, and the presynaptic neuronal
membrane marker anti-HRP (green). B: Quantification of NMJ size, measured from anti-HRP immunofluorescence. C: Number of active zones per NMJ,
quantified by counting BRP puncta in each NMJ. D: Active zone density, measured by dividing number of active zones in each NMJ by the area of
each NMJ. E: Active zone size, quantified by measuring area of every BRP punctum in each 6/7 NMJ. Numbers in parentheses represent either the
number of animals (B-D) or the number of active zones (E; measured from 9-20 animals) examined for each measurement.
doi:10.1371/journal.pone.0011115.g005
Figure 6. Loss of presynaptic neurexin in embryo disrupts synaptic transmission. A: Representative electrophysiological recordings of
stimulus evoked synaptic currents (generated by electrical stimulation of presynaptic motor nerves), and spontaneous excitatory junction currents
(sEJCs), from wild type embryonic NMJs and after disruption of neurexin expression. B: Quantification of EJC amplitude. C: Quantification of sEJC
frequency. Numbers in parentheses represent the number of animals from which each measurement was made.
doi:10.1371/journal.pone.0011115.g006
Drosophila Neurexin
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596 ms; ElavGal4/nrx.RNAi=478–1033 ms; nrx[313]/Df=43–716;
Df/Df=535–1297 ms). These data, along with the data from
Figures 6 and 8, suggest that pre or postsynaptic loss of neurexin
causes an increase in A-type glutamate receptor expression, but these
excess receptors may not function properly or be localized directly
opposite presynaptic sites of neurotransmitter release.
Discussion
The first complete knockout of neurexin function was achieved in
Drosophila, and Zeng et al (2007) provided the first report of
Drosophila neurexin mutants. Using western blots and immunohis-
tochemistry, Zeng et al (2007) showed that neurexin mutants had
reduced brp expression in larval brain, and reduced synapse density
in adult brain [36]. Both results are consistent with the idea that
neurexin promotessynapseformationormaintenance,aspreviously
argued by many studies in mammalian cells and alpha neurexin
mouse mutants [30,31,35,50,51,52,53,54]. Li et al (2007) subse-
quently provided a detailed examination of neurexin mutant larval
NMJs, and showed that larval NMJ arborizations were smaller,
similar to what we describe here in embryos (Fig. 5). Sun et al (2009)
alsoreported smallerNMJs inlarval neurexinmutants. However, Li
et al (2007) reported a large increase in the number of presynaptic
densities (‘T-bars’) and boutons (with no obvious decrease in active
zone density per bouton) in neurexin mutant larval NMJs, which
contrasts with the idea that neurexin promotes synaptogenesis and
our observation that the number of presynaptic densities (measured
either by EM or brp staining) is reduced in neurexin mutant
embryonic NMJs. The proliferation of active zones observed in
neurexin mutant larvae may therefore represent developmental
compensation for reduced muscle excitation. Increased active zone
proliferation during larval development has previously been
observed in other mutants with reduced NMJ transmission [55].
Li et al (2007) also described apparent disruptions in cell
adhesion between presynaptic neurons and postsynaptic muscle in
larval neurexin mutant NMJs, which appeared as widened
synaptic clefts visible by electron microscopy [37]. We observed
no such changes in any of the dozens of sections from 14 separate
embryonic NMJs that we examined. The comparison suggests that
these ultrastructural changes may occur during larval development
rather than initial synapse formation.
Mouse alpha neurexin mutants show dramatic defects in
calcium-dependent neurotransmitter release [50,53]. Drosophila
neurexin mutants also show reductions in neurotransmitter
release, both at the larval stage [37,39], and in embryos (Fig. 6).
In embryos, decreased neurotransmission in neurexin mutant
NMJs appears entirely attributable to the decrease in NMJ active
zone number that we observed (Fig. 5). In older stages, and in
mammals, some of the decreased neurotransmitter release is
attributed to defects in calcium-secretion coupling [37,50,53].
Miniature postsynaptic potentials are larger in larval neurexin
mutant NMJs [37,39]. In contrast, we observed no change in
embryonic neurexin mutant sEJC amplitude, and no change in the
size of individual receptor cluster sizes that typically go along with
such changes. Instead, we saw an increase in the number of
postsynaptic receptor clusters (Fig. 8) without any corresponding
increase in presynaptic active zones. Our data, taken together with
larval results, suggests that loss of neurexin initially causes an
increase in nonfunctional postsynaptic receptor clusters. During
larval development, many of these receptor clusters then become
paired with presynaptic active zones, so that there is an increase in
synapse number as described by Li et al (2007). At this stage,
increased receptor expression is manifest as an increase in
individual receptor cluster sizes and miniature postsynaptic
potentials. Besides the insights into neurexin function, this is
interesting because it suggests that glutamate receptors in embryos
can semi-autonomously form clusters, but receptors in larvae are
preferentially added to pre-existing synapses.
Importantly, our data demonstrate that neurexin mutant
glutamate receptor phenotypes, at least in embryos, are restricted
to A-type receptors. This suggests a mechanism. Drosophila A-type,
but not B-type, glutamate receptors depend on postsynaptic F-
actin for localization/stabilization [47], and this process involves a
direct interaction between the C-terminus of GluRIIA and the
Drosophila 4.1 protein ‘coracle’ [47]. The intracellular C-terminus
of mammalian neurexin has been shown to bind to the PDZ
domain protein CASK [26], and interactions between mammalian
neurexin and CASK in combination with 4.1 protein have been
shown to nucleate F-actin assembly [56]. CASK knockout mice
are lethal but show no dramatic synaptic alterations except
increased neuroligin protein levels and higher spontaneous event
frequency at glutamatergic synapses [57], consistent with our data
and a subtle role in synaptic protein organization. The Drosophila
Figure 7. Calcium dependence of embryonic synapse transmission in neurexin mutants. A: EJCs recorded from both wildtype and
neurexin mutant animals were significantly larger in 5 mM extracellular calcium, compared to 1.8 mM extracellular calcium. sEJC frequencies were
also increased in 5 mM calcium (compare traces to Fig. 6). B: Quantification of EJC amplitudes from wildtype and neurexin mutant animals, in normal
(1.8 mM) and high (5 mM) calcium. High calcium caused EJC amplitudes in both genotypes to increase approximately 3.7-fold. C: Quantification of
sEJC frequency from wildtype and neurexin mutant animals, in normal (1.8 mM) and high (5 mM) calcium. High calcium caused sEJC frequency in
both genotypes to increase approximately 2.3-fold. D: Quantification of sEJC amplitude (which represents, in part, multivesicular events) from
wildtype and neurexin mutant animals, in normal (1.8 mM) and high (5 mM) calcium. High calcium caused sEJC amplitude in both genotypes to
increase approximately 1.55-fold. The calcium-dependent increases within each genotype were statistically significant for all measurements (B-D), but
the fold increase between genotypes was not statistically significant for any experiment (B-D), suggesting that WT and neurexin mutants functionally
respond the same way to increased extracellular calcium. Numbers in parentheses represent the number of animals from which each measurement
was made.
doi:10.1371/journal.pone.0011115.g007
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neurexin to regulate walking behavior and neuromuscular
transmission [39,58,59]. Drosophila neurexin may therefore work
with CASK and coracle (4.1) to regulate A-type glutamate
receptor organization via actin rearrangements. Mammalian beta
neurexin also appears to regulate AMPA receptor abundance in a
subunit-specific manner [60], and alpha neurexin appears to
regulate NMDA but not AMPA receptor function [51]. But in
these cases receptors are recruited by the presence of neurexin
rather than repressed, as is seen in Drosophila. This added
complexity may be due to differing molecular functions of
neurexin within pre and postsynaptic cells. Interestingly, complete
loss of neurexin in both pre and postsynaptic cells led to the same
150–200% increase in GluRIIA as loss of either pre or
postsynaptic neurexin (Fig. 8A). The increase in GluRIIA
immunoreactivity observed after loss of neurexin on any side of
the synapse might therefore represent a physiological limit, or
(more likely) either pre or postsynaptic neurexin is sufficient to
suppress GluRIIA in WT animals.
The most controversial suggestion provided by our data is the
possibility that neurexin in Drosophila NMJs might be present in
postsynaptic muscle, where it appears to contribute (along with
presynaptic neurexin) to formation of proper glutamate receptor
clusters in embryos. Previous studies did not report neurexin
expression in muscles [36,37]. However, the embryonic cuticle
forms at approximately the same time in development as the body
Figure 8. Abundance and localization of postsynaptic glutamate receptor protein. A: Quantification of total glutamate receptor
immunoreactivity in embryonic muscle 6/7 NMJs, measured from anti-GluRIIC immunoreactivity. B: Number of A-type glutamate receptor clusters per
NMJ, measured by counting number of anti-GluRIIA puncta in each muscle 6/7 NMJ. C: Number of B-type glutamate receptor clusters per NMJ,
measured by counting number of anti-GluRIIB puncta in each muscle 6/7 NMJ. D: A-type glutamate receptor cluster area, measured from anti-GluRIIA
immunoreactivity. E: B-type glutamate receptor cluster area, measured from anti-GluRIIB immunoreactivity. F: Loss of either postsynaptic (24B-Gal4/
nrx1.RNAi) or presynaptic (Elav-Gal4/nrx1.RNAi) neurexin triggers a shift in the ratio of A-type (green) to B-type (magenta) glutamate receptors, such
that A-type glutamate receptors become visibly more abundant (note relative increase in green). G: Loss of either pre or postsynaptic neurexin led to
formation of ectopic (nonsynaptic) glutamate receptor clusters, shown here as GluRIIC immunoreactivity (green) that does not overlap with
immunoreactivity for the active zone marker bruchpilot (BRP). N (in parentheses for each measurement) represents number of animals (A-C) or
number of clusters (D-E).
doi:10.1371/journal.pone.0011115.g008
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PLoS ONE | www.plosone.org 9 June 2010 | Volume 5 | Issue 6 | e11115Figure 9. Changes in GluRIIA after rescuing neurexin expression in null mutant. A: Representative confocal micrographs of muscle 6/7
NMJs stained with antibodies against the neuronal membrane marker anti-HRP (green), or GluRIIA (magenta), in wild type embryos, neurexin mutant
(nrx[313]/nrx[241]) embryos, and in embryos after expression of neurexin cDNA in a neurexin null mutant background (DJ690Gal4/UAS-nrx; nrx[313]/
nrx[241]). B: Quantification of total GluRIIA immunoreactivity in each genotype.
doi:10.1371/journal.pone.0011115.g009
Figure 10. Postsynaptically-expressed neurexin::GFP localizes to NMJs and the C-terminal GFP tag is intracellular. Left panels: N- (top)
and C- (bottom) terminal antibody staining in control larval NMJs. Right panels: N- (top) and C- (bottom) terminal antibody staining in larval NMJs
after postsynaptic expression of GFP-tagged neurexin. Antibodies raised against a neurexin C-terminal epitope more perfectly overlap fluorescence
from GFP-tagged neurexin, compared to immunoreactivity from antibodies raised against a neurexin N-terminal epitope (See methods). This is
consistent with the fact that the C-terminal of neurexin is tagged with GFP, and also contains the epitope for the C-terminal antibody. In addition, N-
terminal immunoreactivity is more apparent in presynaptic terminals whereas C-terminal immunoreactivity is more apparent in postsynaptic muscle,
suggesting tissue-specific differences in epitope accessibility, possibly due to tissue-specific differences in interactions between neurexin and other
proteins.
doi:10.1371/journal.pone.0011115.g010
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tissues, making it difficult to detect expression of muscle genes that
are expressed late in embryonic development. Indeed, we also
initially found it difficult to unambiguously detect neurexin
expression in body wall muscles of intact embryos by in situ
hybridization. Previous studies did not test explicitly whether
postsynaptic neurexin affected postsynaptic receptor clustering,
but agree with our result that postsynaptic neurexin does not affect
presynaptic differentiation or function. Taniguchi et al (2007) also
suggested that neurexin might function postsynaptically in
mammalian cells. Specifically, they suggested that postsynaptic
neurexin could interact with postsynaptic neuroligin to reduce
transsynaptic neurexin-neuroligin interactions [61]. This hypoth-
esis does not quite fit with our data, however, since we observed
that knockdown of presynaptic neurexin and postsynaptic
neurexin had the same receptor phenotype. If postsynaptic
neurexin counteracted presynaptic neurexin function, one would
expect postsynaptic neurexin knockdown to have the opposite
effect of presynaptic neurexin knockdown. The simplest hypothesis
that allows for all the results is that presynaptic neurexin works via
transynaptic interactions (with neuroligin or other proteins), while
postsynaptic neurexin works primarily via intracellular C-terminal
interactions to regulate receptor clustering, as hypothesized above.
Note that these postsynaptic neurexin intracellular interactions do
not exclude any previously demonstrated interactions between the
intracellular C-terminus of postsynaptic neuroligin and other
proteins, including PSD-95 [32,33,34,35,62].
Materials and Methods
In situ hybridization
To produce the in situ probes pSL nrx-1 was digested with EcoRI
and XbaI and the fragment ligated into pBluescript II KS+. The
final vector (pKs+ Nrx-1) was cut with EcoRI to make the antisense
probe with T7 (59-AAT ACG ACT CAC TAT AG-39). The sense
control probe was made with T3 (59- ATT AAC CCT CAC TAA
AGG GA-39) after cutting pKS+ Nrx-1 with XbaI. In situs were
performed following the Berkeley Drosophila Genome Project (BDGP)
standard methods (http://www.fruitfly.org/about/methods/index.
html). Following hybridization, embryos were manually staged and
dissected to examine neurexin expression. Dissections were per-
formed as for confocal imaging and electrophysiology (described
below).
Immunohistochemistry and confocal microscopy
For immunohistochemistry and confocal microscopy, animals
were manually dissected and fixed in Bouin’s fixative as previously
described [46,47]. Neurexin ‘N-terminus’ polyclonal antibodies
were raised in rabbits against the synthetic neurexin-specific
peptide ELRLLPAQRTSTSAFESPDLR and affinity purified by
Open Biosystems (Huntsville AL). Neurexin ‘C-terminus’ poly-
clonal antibodies were generated and affinity purified the same
way, but the neurexin - specific peptide used as an antigen was
QPKAKKRDSKDVKEWYV. Anti-NRX antibodies were used
at 1:500 in late stage embryos (22–24 h after egg laying (AEL) at
25C, temporally and morphologically staged). Mouse monoclonal
anti-GluRIIA, from a cell line made by Christoph Schuster and
available from University of Iowa’s Developmental Studies
Hybridoma Bank (DSHB), was used at 1:100 [63]. Rabbit
polyclonal anti-GluRIIB and rabbit polyclonal anti-GluRIIC, first
described in Marrus et al (2004) and subsequently replicated in the
lab of D.E.F., were used at 1:2000 [43]. Mouse NC82 (anti-
bruchpilot), a gift from Eric Buchner, was used at 1:100 [48].
Fluorescently-conjugated anti-HRP (Jackson Immuno laborato-
ries, West Grove PA) was used at 1:200. Immunoreactivity was
visualized using FITC-, TRITC-, or CY5-conjugated goat anti-
mouse/rabbit secondary antibodies (Jackson Immuno Laborato-
ries), used at 1:400–1:2000. All images of NMJs are from ventral
Figure 11. Postsynaptic overexpression of neurexin reduces the number of A-type, but not B-type receptors in larval NMJs. A: Anti-
GluRIIA immunoreactivity is increased in 24BGal4/UAS-NRX::GFP larval NMJs, which overexpress GFP-tagged neurexin specifically in postsynaptic
muscle. B: Anti-GluRIIB immunoreactivity is unchanged after postsynaptic overexpression of neurexin.
doi:10.1371/journal.pone.0011115.g011
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and experimental preparations were always stained and imaged in
parallel.
Images were captured using an Olympus Fluoview FV500 laser
scanning confocal system. Quantifications of staining intensity
were performed as previously described (46). Briefly, fluorescence
intensity of relevant structures from unaltered unsaturated
confocal maximum intensity projections was measured by
manually selecting the region of interest in imageJ and measuring
mean pixel intensity of that region. To control for differences in
individual preparation immunoreactivity, excitation, fluorescence
attenuation, and detection, we then subtracted mean pixel
intensity of a similarly-sized region of unstained ‘background’ in
the same fluorescence wavelength channel in the same image.
Immunohistochemical measurement of active zone and GluR
cluster size was also done as previously described [63,46,47].
Briefly, ImageJ software was used to manually outline every
puncta visible on a 6/7 NMJ. The puncta area (in pixels) was then
measured and converted to square micrometers based on pixel size
values computed for each image by Fluoview confocal software,
which automatically records image resolution, microscope objec-
tive, and ‘zoom’ factor for each image. Muscle 6/7 NMJ sizes were
similarly measured, using synaptic anti-HRP fluorescence. Photo-
shop CS2 was then used to crop images and adjust contrast for
final display.
Electron microscopy
For electron microscopy, genotyped Drosophila eggs were
dechorionated with bleach and manually devitellinated before
immersion in a bacteria slurry for HPF/FS. High pressure
freezing, freeze substitution (HPF/FS), and transmission electron
microscopy (TEM) were performed as previously described for C.
elegans [64,65]. Briefly: Fixed whole embryos were thin sectioned
(40–50 nm) onto formvar-coated copper grids and counterstained
using 2.5% uranyl acetate and Reynold’s lead citrate. Images were
collected from late embryonic (22–24 h AEL) body wall NMJs in
abdominal segments, selected based on proximity to cuticle
midway along the longitudinal axis of the embryo. For immuno
EM analysis, animals were fixed with 0.1% potassium permanga-
nate for 72 hours and embedded in Lowicryl for 60 hours under
UV light. Thin (,50 nm) sections from Lowicryl embedded
samples were collected as ribbons on formvar-coated nickel slot
grids and immuno-gold labeled in a similar fashion to that
described previously [66]. The neurexin antibody was used at a
dilution of 1:30. Anti-rabbit-10 nm gold bead conjugated
antibodies were diluted 1:150.
Generation of UAS-nrx1.RNAi
UAS-nrx.RNAi flies were generous gifts from Mary Gilbert and
Vanessa Auld (University of British Columbia, Canada). The UAS-
Figure 12. Loss of neurexin causes little change in the number of functional postsynaptic receptors. A: Representative
electrophysiological recordings of glutamate-gated currents triggered by pressure ejection of 1 mM glutamate onto patch-clamped embryonic
muscle 6. B: Quantification of spontaneous synaptic current (sEJC) amplitude, measured from recordings such as those shown in figure 6A. C:
Quantification of glutamate-gated current amplitude (elicited by pressure ejection of 1 mM glutamate onto NMJs). Numbers in parentheses
represent the number of animals from which each measurement was made.
doi:10.1371/journal.pone.0011115.g012
Drosophila Neurexin
PLoS ONE | www.plosone.org 12 June 2010 | Volume 5 | Issue 6 | e11115nrx.RNAi transgene was created as follows: A 2.1 kb genomic
fragment of neurexin 1 was amplified using PCR from EP(3)0709
genomic DNA using oligonucleotides RINrx (RINrx: 59-
GAATTCTAACCGTGGATGACTCCTTC-39) and XhoNrx
(XhoNrx: 59-CTCGAGCGAGAAGATCAGATCGTCCA-39),
then subcloned into pGEM-T using standard methods. A genomic
fragment was subsequently excised from pGEM-T with SalI (59
end) and XhoI (39 end) and subcloned directionally into pBS KS+
(Stratagene). This genomic fragment was then excised from pBS
with XbaI (59end) and XhoI (39 end) and directionally subcloned
into an intermediate RNAi plasmid provided by Genetic Services
Inc (Sudbury, MA, USA), to generate the tail-to-tail pNrxRNAi
plasmid which was then transformed w1118 Drosophila embryos.
Ten viable transformed lines were produced. All experiments
described in this manuscript used line #5.
Neurexin mutant alleles
Many of the experiments in this study used previously-
undescribed nrx[313] mutants. This mutation (and several other
alleles) was generated by mobilization of P{Mi}Nrx-1{MB00002},
using standard methods (50, 51), with the exception that we used
the PhsILMiT transposase source required for minos mobilization.
PhsILMiT flies were generously provided by the lab of Dr. H.
Bellen (Baylor College of Medicine), whose lab also produced and
provided P{Mi}Nrx-1{MB00002} flies as part of the ongoing
BDGP Gene Disruption Project (23). The Minos element and
PhsILMiT transgenes were provided by Minos Biosystems Ltd
(Glasgow, Scotland). Neurexin mutants, including nrx[313], were
selected after P{Mi}Nrx-1{MB00002} mobilization based on loss/
alteration in minos element eGFP expression (indicating that the
transposon had changed location) and loss of neurexin immunor-
eactivity.Df(3R)Exel6191 mutants were obtained from the Bloo-
mington Drosophila Stock Center. nrx[241] mutants, described in Li
et al (2007), were a generous gift from Manzoor Bhat.
We sequenced the neurexin genomic region in wildtype embryos,
homozygous nrx[313] mutants, and flies in which P{Mi}Nrx-
1{MB00002} was excised with no phenotype (e.g. precise excision
animals). Sequences from these three genotypes were compared to
each other and to the reference sequence from the Drosophila
genome project. As expected, P{Mi}Nrx-1{MB00002} was
completely excised in nrx[313] mutants. Surprisingly, we detected
only a relatively small genomic alteration in nrx[313] mutant
chromosomes: a 10 bp deletion in neurexin intron #7, approxi-
mately 3 kb from the original P{Mi}Nrx- 1{MB00002} insertion
site. Genscan (52) predicted that this deletion (loss of CAGCTG-
CAAC) would cause no change in neurexin splicing. However,
inspection with VISTA comparative genomics tools (53) revealed
that the nrx[313] deletion removes a stretch of very highly
conserved intronic sequence. This sequence stretch has 95–100%
base pair conservation between different Drosophila species --
higher than that found in most neurexin exons. Thus, it likely
represents a previously unidentified essential regulatory sequence.
To confirm that this small deletion represents a true loss-of-
function mutation for neurexin, we performed complementation
tests with two other molecularly characterized neurexin null alleles,
Df(3R)Exel6191 and nrx[241], and used neurexin antibodies to
quantify neurexin protein immunoreactivity in the NMJ of each
genotype (Fig. 3). Df(3R)Exel6191 removes the entire neurexin
gene region; nrx[241] is a precise deletion of the neurexin coding
region (21). As expected, nrx[313] failed to complement either of
these other alleles, either with regard to NMJ neurexin staining or
any of the major neurexin mutant phenotypes. nrx[313] is
therefore unambiguously a neurexin null allele, based on both
genetic and phenotypic criteria.
Electrophysiology
Patch clamp electrophysiology on late embryonic (22–24 h
AEL) NMJs was performed as previously described [47,67].
Briefly, muscle 6 was whole-cell voltage clamped at 260 mV in
standard Drosophila saline (135 mM NaCl, 5 mM KCl, 4 mM
MgCl2, 1.8 mM CaCl2, 72 sucrose, and 5 TES, pH 7.2). Where
noted, extracellular calcium was increased to 5 mM. The patch
pipette solution contained (in mM): 120 KCl, 20 KOH, 4 MgCl2,
0.25 CaCl2, 5 EGTA, 36 sucrose, and 5 TES. Evoked synaptic
currents were triggered by 5–10 V electrical stimulation of the
appropriate segmental nerve using a suction electrode, as
previously described (46). Glutamate-gated currents were evoked
by pressure ejection of 1 mM glutamate onto NMJs using small
glass pipettes and a picospritzer II, as previously described [68].
Statistics
Statistical significance was determined using unpaired Student t-
tests (for normally distributed data) or nonparametric Mann
Whitney tests (when post-hoc F-tests determined that variances
were significantly different). In all figures, asterisks indicate
statistical significance: ***=p,0.001, **=p,0.01, *=p,0.05.
N for each measurement is indicated in each figure (N=number
in parentheses). In all cases, unless stated otherwise, N=the
number of different animals from which measurements were
taken. Error bars represent standard error of the mean (S.E.M.).
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